Evaluation of the analgesic effect of 4-anilidopiperidine scaffold containing ureas and carbamates

References

• Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol 2008;16:405–16
   PubMed Web of Science ®Google Scholar
• (a) Vucković S, Prostran M, Ivanović M, et al. Pharmacological evaluation of 3-carbomethoxy fentanyl in mice. Curr Med Chem 2009;16:2468–74. (b) Casy AF, Parfitt RT. Opioid analgesics: chemistry and receptors. New York: Springer; 1986
   Google Scholar
• (a) Subramaniam A. Opioid ligands with mixed m/d opioid receptor interactions: an emerging approach to novel analgesics. AAPS J 2006;8:118–25. (b) van Rijn RM, DeFriel JN, Whistler JL. Pharmacological traits of delta opioid receptors: pitfalls or opportunities? Psychopharmacology (Berl) 2013;228:1–18. (c) Gomes I, Gupta A, Filipovska J, et al. A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci USA 2004;101:5135–9
   Web of Science ®Google Scholar
• (a) Mollica A, Pinnen F, Feliciani F, et al. New potent biphalin analogues containing p-fluoro-L-phenylalanine at the 4,4' positions and non-hydrazine linkers. Amino Acids 2010;40:1503–11. (b) Mollica A, Pinnen F, Costante R, et al. Biological active analogues of the opioid peptide biphalin: mixed α/β(3)-peptides. J Med Chem 2013;56:3419–23. (c) Mollica A, Costante R, Stefanucci A, et al. Antinociceptive profile of potent opioid peptide AM94, a fluorinated analogue of biphalin with non-hydrazine linker. J Pept Sci 2013;19:233–9. (d) Mollica A, Costante R, Novellino E, et al. Design, synthesis and biological evaluation of two opioid agonist and Cav 2.2 blocker multitarget ligands. Chem Biol Drug Des 2015;86:156–62
   PubMed Web of Science ®Google Scholar
• (a) Petrov RR, Lee YS, Vardanyan RS, et al. Effect of anchoring 4-anilidopiperidines to opioid peptides. Bioorg Med Chem Lett 2013;23:3434–7. (b) Podolsky AT, Sandweiss A, Hu J, et al. Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain. Life Sci 2013;93:1010–6. (c) Deekonda S, Wugalter L, Rankin D, et al. Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives. Bioorg Med Chem Lett 2015;25:4683–8
   PubMed Web of Science ®Google Scholar
• (a) Parker KE, McCall JG, McGuirk SR, et al. Effects of co-administration of 2-arachidonylglycerol (2-AG) and a selective μ-opioid receptor agonist into the nucleus accumbens on high-fat feeding behaviors in the rat. Brain Res 2015;1618:309–15. (b) Scavone JL, Sterling RC, Van Bockstaele EJ. Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience 2013;248:637–54
   PubMed Web of Science ®Google Scholar
• Dvoracsko S, Stefanucci A, Novellino E, Mollica A. The design of multitarget ligands for chronic and neuropathic pain. Future Med Chem 2015;7:2469–83
   PubMed Web of Science ®Google Scholar
• (a) Ahn K, Johnson DS, Mileni M, et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 2009;16:411–20. (b) Karlsson J, Morgillo CM, Deplano A, et al. Interaction of the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and ibuprofen with FAAH: enantiomeric selectivity and binding mode. PLoS One 2015;10:e0142711
   PubMed Web of Science ®Google Scholar
• Ahn K, Johnson DS, Cravatt BF. Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opin Drug Discov 2009;4:763–84
   PubMed Web of Science ®Google Scholar
• a) Ligresti A, Morera E, Van Der Stelt M, et al. Further evidence for the existence of a specific process for the membrane transport of anandamide. Biochem J 2004;15:265–72. (b) Maione S, Morera E, Marabese I, et al. Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and non-cannabinoid receptor-mediated mechanisms. Br J Pharmacol 2008;155:775–82. (c) Morera E, Petrocellis LD, Morera L, et al. Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands. Bioorg Med Chem Lett 2009;19:6806–9. (d) Gustin DJ, Ma Z, Min X, et al. Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors. Bioorg Chem Chem Lett 2011;21:2492–6
   Web of Science ®Google Scholar
• Jagerovic N, Fernández-Fernández C, Erdozain AM, et al. Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results. Drug Des Devel Ther 2014;8:263–77
   PubMed Web of Science ®Google Scholar
• Rinaldi-Carmona M, Barth F, Héaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994;350:240–4
   PubMed Web of Science ®Google Scholar
• (a) Cinar R, Szücs M. CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells. J Pharmacol Exp Ther 2009;330:567–74. (b) Erdozain AM, Diez-Alarcia R, Meana JJ, Callado LF. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain. Biochem Pharmacol 2012;83:260–8. (c) Zádor F, Kocsis D, Borsodi A, Benyhe S. Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity. Neurochem Int 2014;67:14–22
   PubMed Web of Science ®Google Scholar
• Lange JHM, Kruse CG. Keynote review: medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discov Today 2005;10:693–702
   PubMed Web of Science ®Google Scholar
• Dosen-Micovic L, Ivanovic M, Micovic V. Steric interactions and the activity of fentanyl analogs at the mu-opioid receptor. Bioorg Med Chem 2006;14:2887–95
   PubMed Web of Science ®Google Scholar
• Jensen TS, Finnerup NB. Neuropathic pain treatment: a further step forward. Lancet 2009;374:1218–19
   PubMed Web of Science ®Google Scholar
• Mollica A, Stefanucci A, Costante R, Hruby VJ. Rational approach to the design of bioactive peptidomimetics: recent developments in opioid agonist peptides. Elsevier; 2014, p. 27
   Google Scholar
• (a) Vardanyan RS, Hruby VJ. Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications. Future Med Chem 2014;6:385–412. (b) Ioja E, Tourwé D, Kertész I, et al. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity. Brain Res Bull 2007;74:119–29
   PubMed Web of Science ®Google Scholar
• Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 1993;234:779–815
   PubMed Web of Science ®Google Scholar
• Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31:455–61
   PubMed Web of Science ®Google Scholar
• Sanner FM Python: a programming language for software integration and development. . J Mol Graph Model 1999;17:57–61
   PubMed Web of Science ®Google Scholar
• Hanwell MD, Curtis DE, Lonie DC, et al. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J Cheminform 2012;4:17
   PubMed Web of Science ®Google Scholar
• Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996;14:33–8
   PubMed Web of Science ®Google Scholar
• Sanner MF, Spehner J-C, Olson AJ. Reduced surface: an efficient way to compute molecular surfaces. Biopolymers 1996;38:305–20
   PubMed Web of Science ®Google Scholar
• R Development Core Team (2008); R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. Available from: http://www.R-project.org
   Google Scholar
• Benyhe S, Farkas J, Tóth G, Wollemann M. Met5-enkephalin-Arg6-Phe7, an endogenous neuropeptide, binds to multiple opioid and nonopioid sites in rat brain. J Neurosci Res 1997;48:249–58
   PubMed Web of Science ®Google Scholar
• Zádor F, Kocsis D, Borsodi A, Benyhe S. Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity. Neurochem Int 2014;67:14–22
   PubMed Web of Science ®Google Scholar
• Sim LJ, Selley DE, Childers SR. In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding. Proc Natl Acad Sci USA 1995;92:7242–6
   PubMed Web of Science ®Google Scholar
• Traynor JR, Nahorski SR. Modulation by m-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol 1995;47:848–54
   PubMed Web of Science ®Google Scholar
• Foran SE, Carr DB, Lipkowski AW, et al. Inhibition of morphine tolerance development by a substance P-opioid peptide chimera. J Pharmacol Exp Ther 2000;295:1142–8
   PubMed Web of Science ®Google Scholar
• Yaksh TL, Rudy TA. Chronic catheterization of the spinal subarachnoid space. \Physiol Behav 1976;17:1031–6
   PubMed Web of Science ®Google Scholar
• Porreca F, Mosberg HI, Hurst R, et al. Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J Pharmacol Exp Ther 1984;230:341–8
   PubMed Web of Science ®Google Scholar